Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND)
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Efavirenz (EFV) is among the most commonly used antiretroviral drugs globally, causes neurological symptoms that interfere with adherence and reduce tolerability, and may have central nervous system (CNS) effects that contribute in part to HIV associated neurocognitive disorders (HAND) in patients on combination antiretroviral therapy (cART). Thus we evaluated a commonly used EFV containing regimen: EFV/zidovudine (AZT)/lamivudine (3TC) in murine N2a cells transfected with the human "Swedish" mutant form of amyloid precursor protein (SweAPP N2a cells) to assess for promotion of amyloid-beta (Aβ) production. Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Aβ), and promoted increased β-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints. Further, EFV or the EFV containing regimen promoted significantly more mitochondrial stress in SweAPP N2a cells as compared to 3TC, AZT, or vehicle control. We next tested the EFV containing regimen in Aβ - producing Tg2576 mice combined or singly using clinically relevant doses. EFV or the EFV containing regimen promoted significantly more BACE-1 expression and soluble Aβ generation while 3TC, AZT, or vehicle control did not. Finally, microglial Aβ phagocytosis was significantly reduced by EFV or the EFV containing regimen but not by AZT, 3TC, or vehicle control alone. These data suggest the majority of Aβ promoting effects of this cART regimen are dependent upon EFV as it promotes both increased production, and decreased clearance of Aβ peptide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
Microglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis
Mandrekar, S., Jiang, Q., Lee, C. Y. D., Koenigsknecht-Talboo, J., Holtzman, D. M., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5572-08.2009 · Cited by 415 · cited 1×
“Amyloid load in the brain is affected not only by production, but also by its clearance from the brain via microglia mediated mechanisms [66].”
BackgroundFagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327
Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients
Green, D. A., Masliah, E., Vinters, H. V., Beizai, P., Moore, D. J., & Achim, C. L. (2005) · AIDS · doi:10.1097/01.aids.0000161770.06158.5c · Cited by 299 · cited 1×
“Possible reasons for the absence of (11)C-PiB in HIV patients are: 1) decreased Ab1-42 production secondary to decreased synaptic activity, 2) increased intraneuronal Ab1-42 deposition that is undetectable by (11)C-PiB [37]; and/or 3) increased Ab1-42 brain deposition but in a more diffuse, nonfibrillar form that is u…”
BackgroundGrimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278
Risk Factors for β-Amyloid Deposition in Healthy Aging: Vascular and Genetic Effects
Rodrigue, K. M., Rieck, J. R., Kennedy, K. M., Devous, M. D., Diaz-Arrastia, R., & Park, D. C. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1342 · Cited by 249
Increased Accumulation of Intraneuronal Amyloid β in HIV-Infected Patients
HNRC, Achim, C. L., Adame, A., Dumaop, W., Everall, I. P., & Masliah, E. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9152-8 · Cited by 205 · cited 2×
“Possible reasons for the absence of (11)C-PiB in HIV patients are: 1) decreased Ab1-42 production secondary to decreased synaptic activity, 2) increased intraneuronal Ab1-42 deposition that is undetectable by (11)C-PiB [37]; and/or 3) increased Ab1-42 brain deposition but in a more diffuse, nonfibrillar form that is u…”
BackgroundAnthony, I. C., Ramage, S. N., Carnie, F. W., Simmonds, P., & Bell, J. E. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0037-0 · Cited by 158
Suo, Z., Tan, J., Placzek, A., Crawford, F., Fang, C., & Mullan, M. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00780-x · Cited by 116
Self-citation
Cited by
Efavirenz: what is known about the cellular mechanisms responsible for its adverse effects
Apostolova, N., Blas-Garcia, A., Galindo, M. J., & Esplugues, J. V. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.016 · Cited by 49
Blood amyloid-β protein isoforms are affected by HIV-1 in a subtype-dependent pattern
The HIV Neurobehavioral Research Center (HNRC) Group, de Almeida, S. M., Ribeiro, C. E., Rotta, I., Letendre, S., Potter, M., Tang, B., Batistela, M., Vaida, F., & Ellis, R. J. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-019-00783-6 · Cited by 14
van de Wijer, L., Garcia, L. P., Hanswijk, S. I., Rando, J., Middelman, A., ter Heine, R., Mast, Q. D., Martens, G. J. M., van der Ven, A. J. A. M., Kolk, S. M., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0420-y · Cited by 13
Metadata
- Authors
- Brown, L. A. M., Jin, J., Ferrell, D., Sadic, E., Obregon, D., Smith, A. J., Tan, J., & Giunta, B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-04-23
- Volume
- 9
- Issue
- 4
- Pages
- e95500
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2033265046
- Cited by
- 59
- References
- 12
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.